Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., & Loebel, A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060770 · Cited by 322
Lenze, E. J., Mulsant, B. H., Blumberger, D. M., Karp, J. F., Newcomer, J. W., Anderson, S. J., Dew, M. A., Butters, M. A., Stack, J. A., Begley, A. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00308-6 · Cited by 283 · cited 1×
“TRD patients older than 60 years old were randomized into two groups: venlafaxine extended-release (ER) with aripirazole or venlafaxine ER with a placebo.(29) The results showed a greater proportion of the participants in the aripiprazole group achieved remission than did those in the placebo group (44% vs.”
MethodSpielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression
Ostroff, R. B., & Nelson, J. C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0410 · Cited by 248
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09204 · Cited by 189 · cited 2×
“Zhou et al.(85) sought to investigate this important issue using network meta-analysis.”
BackgroundThase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182 · cited 1×
“The two studies were identical in design and were conducted by the same research group.(17,18) In both studies, subjects included had a history of inadequate response to 1-3 treatment trials of standard antidepressant medications for their current depressive episode.”
ResultCorya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170 · cited 1×
“49 The remaining four studies, including study 2 by Thase, showed that an olanzapine/fluoxetine combination produced significantly greater improvement than its comparator including olanzapine and fluoxetine monotherapy, 5,47-49 nortriptyline,(47) or venlafaxine.(48) In addition, three RPCTs (two identically designed s…”
ResultCorya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140 · cited 1×
“Two studies showed superior efficacy of risperidone augmentation to current antidepressants compared to placebo in response and remission among treatment resistant depression or difficult to treat depression.(63,64) One study showed the efficacy of risperidone augmentation for TRD versus a placebo treatment in decreas…”
ResultKeitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108 · cited 1×
“Two studies showed superior efficacy of risperidone augmentation to current antidepressants compared to placebo in response and remission among treatment resistant depression or difficult to treat depression.(63,64) One study showed the efficacy of risperidone augmentation for TRD versus a placebo treatment in decreas…”
ResultReeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102 · cited 1×
“One study showed the efficacy of risperidone augmentation for TRD versus a placebo treatment in decrease suicidality.(65) Two studies tested the efficacy of risperidone augmentation as maintenance therapy versus placebo.”
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-160 · Cited by 51
McIntyre, A., Paisley, D., Kouassi, E., & Gendron, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38228 · Cited by 43 · cited 2×
“For instance, the effects of quetiapine XR was recently shown in an 8-week RPCT in patients with MDD comorbid with fibromyalgia.(44) All measures of depressive symptoms, pain, and quality of life were more significantly improved in the quetiapine XR group than in the placebo group.”
BackgroundMethodHeo, J.-Y., Jeon, H. J., Fava, M., Mischoulon, D., Baer, L., Clain, A., Doorley, J., Pisoni, A., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.01.007 · Cited by 6
Cited by
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Cheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz062 · Cited by 38
Metadata
- Authors
- Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U.
- Venue
- Chonnam Medical Journal
- Published
- 2016
- Volume
- 52
- Issue
- 3
- Pages
- 159
- ISSN
- 0377-9564 (ISSN-L)
- 2233-7385
- 2233-7393
- OpenAlex
- W2526466306
- Cited by
- 56
- References
- 20
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.